Cargando…
Patients at risk of chemotherapy-associated toxicity in small cell lung cancer.
During a clinical trial of duration of chemotherapy in small cell lung cancer (SCLC), 71 of 610 patients (11.6%) died in the first 3 weeks. Chemotherapy consisted of cyclophosphamide 1 g m-2 i.v. day 1, etoposide 100 mg t.d.s. orally days 1-3, vincristine 2 mg i.v. day 1. The time of death was found...
Autores principales: | , , , , , , , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
1989
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2247207/ https://www.ncbi.nlm.nih.gov/pubmed/2544222 |
_version_ | 1782150932439498752 |
---|---|
author | Morittu, L. Earl, H. M. Souhami, R. L. Ash, C. M. Tobias, J. S. Geddes, D. M. Harper, P. G. Spiro, S. G. |
author_facet | Morittu, L. Earl, H. M. Souhami, R. L. Ash, C. M. Tobias, J. S. Geddes, D. M. Harper, P. G. Spiro, S. G. |
author_sort | Morittu, L. |
collection | PubMed |
description | During a clinical trial of duration of chemotherapy in small cell lung cancer (SCLC), 71 of 610 patients (11.6%) died in the first 3 weeks. Chemotherapy consisted of cyclophosphamide 1 g m-2 i.v. day 1, etoposide 100 mg t.d.s. orally days 1-3, vincristine 2 mg i.v. day 1. The time of death was found to be nonrandomly distributed within the first chemotherapy cycle, with a peak incidence between days 7 and 12 after chemotherapy. Patients were matched with controls who were the next cases entered into the study who did not die in the first 3 weeks. Patients dying early were more likely to have clinical hepatomegaly (P less than 0.0001), and ECOG score greater than or equal to 1 (P less than 0.00001). As a group these patients also had a higher alkaline phosphatase (P less than 0.0002), an elevated blood urea (P less than 0.00001) and a lower serum albumin (P less than 0.0001) than controls. It is probable that infection contributes to the death of these already ill patients at a time when the blood count is low. Early deaths have been noted in two other large trials using regimens including etoposide. Prophylactic antibiotics or dosage modification may prevent the early death of these high risk patients. |
format | Text |
id | pubmed-2247207 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 1989 |
publisher | Nature Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-22472072009-09-10 Patients at risk of chemotherapy-associated toxicity in small cell lung cancer. Morittu, L. Earl, H. M. Souhami, R. L. Ash, C. M. Tobias, J. S. Geddes, D. M. Harper, P. G. Spiro, S. G. Br J Cancer Research Article During a clinical trial of duration of chemotherapy in small cell lung cancer (SCLC), 71 of 610 patients (11.6%) died in the first 3 weeks. Chemotherapy consisted of cyclophosphamide 1 g m-2 i.v. day 1, etoposide 100 mg t.d.s. orally days 1-3, vincristine 2 mg i.v. day 1. The time of death was found to be nonrandomly distributed within the first chemotherapy cycle, with a peak incidence between days 7 and 12 after chemotherapy. Patients were matched with controls who were the next cases entered into the study who did not die in the first 3 weeks. Patients dying early were more likely to have clinical hepatomegaly (P less than 0.0001), and ECOG score greater than or equal to 1 (P less than 0.00001). As a group these patients also had a higher alkaline phosphatase (P less than 0.0002), an elevated blood urea (P less than 0.00001) and a lower serum albumin (P less than 0.0001) than controls. It is probable that infection contributes to the death of these already ill patients at a time when the blood count is low. Early deaths have been noted in two other large trials using regimens including etoposide. Prophylactic antibiotics or dosage modification may prevent the early death of these high risk patients. Nature Publishing Group 1989-05 /pmc/articles/PMC2247207/ /pubmed/2544222 Text en https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/. |
spellingShingle | Research Article Morittu, L. Earl, H. M. Souhami, R. L. Ash, C. M. Tobias, J. S. Geddes, D. M. Harper, P. G. Spiro, S. G. Patients at risk of chemotherapy-associated toxicity in small cell lung cancer. |
title | Patients at risk of chemotherapy-associated toxicity in small cell lung cancer. |
title_full | Patients at risk of chemotherapy-associated toxicity in small cell lung cancer. |
title_fullStr | Patients at risk of chemotherapy-associated toxicity in small cell lung cancer. |
title_full_unstemmed | Patients at risk of chemotherapy-associated toxicity in small cell lung cancer. |
title_short | Patients at risk of chemotherapy-associated toxicity in small cell lung cancer. |
title_sort | patients at risk of chemotherapy-associated toxicity in small cell lung cancer. |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2247207/ https://www.ncbi.nlm.nih.gov/pubmed/2544222 |
work_keys_str_mv | AT morittul patientsatriskofchemotherapyassociatedtoxicityinsmallcelllungcancer AT earlhm patientsatriskofchemotherapyassociatedtoxicityinsmallcelllungcancer AT souhamirl patientsatriskofchemotherapyassociatedtoxicityinsmallcelllungcancer AT ashcm patientsatriskofchemotherapyassociatedtoxicityinsmallcelllungcancer AT tobiasjs patientsatriskofchemotherapyassociatedtoxicityinsmallcelllungcancer AT geddesdm patientsatriskofchemotherapyassociatedtoxicityinsmallcelllungcancer AT harperpg patientsatriskofchemotherapyassociatedtoxicityinsmallcelllungcancer AT spirosg patientsatriskofchemotherapyassociatedtoxicityinsmallcelllungcancer |